Please do not leave this page until complete. This can take a few moments.
Pharma giant Pfizer has acquired a California biotech that has developed a treatment for potentially deadly fungal infections in people with compromised immune systems.
Pfizer, which has a large Connecticut presence, said that the deal to acquire San Diego-based Amplyx Pharmaceuticals will allow it to expand its anti-infectives pipeline.
Financial terms were not disclosed.
Amplyx’s lead drug compound fosmanogepix is in Phase 2 clinical trials. The drug aims to treat fungal strains that are resistant to other drugs. The deal also gives Pfizer the company’s early-stage pipeline of antiviral and antifungal therapies.
There has been no new therapeutic class of antifungal therapies approved by the U.S. Food and Drug Administration in nearly 20 years, according to Pfizer.
“We’ve already invested in assets that, if approved, could help address drug-resistant bacterial infections and critical viral infections,” Angela Lukin, global president, Pfizer Hospital, said in a statement. “We look forward to progressing the development of a novel antifungal as well.”
Contact Natalie Missakian at news@newhavenbiz.com
This special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Learn moreHartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
SubscribeDelivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
Read HereThis special edition informs and connects businesses with nonprofit organizations that are aligned with what they care about. Each nonprofit profile provides a crisp snapshot of the organization’s mission, goals, area of service, giving and volunteer opportunities and board leadership.
Hartford Business Journal provides the top coverage of news, trends, data, politics and personalities of the area’s business community. Get the news and information you need from the award-winning writers at HBJ. Don’t miss out - subscribe today.
Delivering Vital Marketplace Content and Context to Senior Decision Makers Throughout Greater Hartford and the State ... All Year Long!
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
In order to use this feature, we need some information from you. You can also login or register for a free account.
By clicking submit you are agreeing to our cookie usage and Privacy Policy
Already have an account? Login
Already have an account? Login
Want to create an account? Register
This website uses cookies to ensure you get the best experience on our website. Our privacy policy
To ensure the best experience on our website, articles cannot be read without allowing cookies. Please allow cookies to continue reading. Our privacy policy
0 Comments